MAS1L is a G protein-coupled receptor localized to the plasma membrane that functions in G protein-coupled receptor signaling pathways 1. In lung adenocarcinoma, MAS1L serves as a characteristic gene associated with lymph node metastasis and functions as a prognostic biomarker 1. Elevated MAS1L expression correlates with better disease-free and progression-free survival in lung cancer patients, and it was incorporated into a three-gene prognostic model alongside TCP10L2 and CRHR2 with predictive efficiency for patient outcomes 1. Beyond cancer, MAS1L has been implicated in immunological disease pathways. Genetic variation in the UBD/MAS1L region on chromosome 6 associates with type 1A diabetes susceptibility, with SNP rs1233478 showing significant association (P = 1.6 × 10⁻²³) independent of HLA class II and class I alleles 2. In myeloproliferative neoplasms, MAS1L expression is dysregulated in JAK2V617F-positive patients and is cis-regulated by specific long non-coding RNAs, suggesting involvement in hematologic malignancy pathogenesis 3. These findings indicate MAS1L participates in both malignant transformation and autoimmune disease mechanisms, though specific molecular mechanisms require further investigation.